Belgian-Dutch pharmaceutical firm argenx said on Thursday that global sales ​of its leading autoimmune drug ‌Vyvgart rose 54% in the third quarter, as it reached more patients.

Log in or sign up to comment.

No comments yet.

← Back to stories

Create FREE account

or login to continue

Signup with GoogleSignup with GitHubSignup with BlueskySignup with Blacksky
Sign up with email

Already have an account? Log in